Aktienanalyse zu Natera Inc (NTRA)NTRANatera Inc

Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Natera Inc is a good buy right now due to its strong revenue growth of 37.7% year-over-year in Q2 2026, reaching $752.8 million, and a favorable analyst price target range of $350 to $365, indicating significant upside potential from the current price of $326.26. The main risk is the high valuation, with a price-to-sales ratio of 18.03, which could limit short-term gains if market sentiment shifts.

6 analysts cover NTRA: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 262.92.